Designing A Discrete Choice Experiment To Measure Patient Preferences And Willingness-To-Pay For Targeted Therapies For Colorectal Cancer In Singapore

Molecularly targeted therapies such as cetuximab and bevacizumab have improved survival for patients with metastatic colorectal cancer (mCRC) significantly. Understanding patient preferences for these treatments as well as their willingness-to-pay is crucial in shared decision making. Discrete Choice Experiment (DCE) is increasingly used in healthcare to elicit preferences as it can simulate real-world trade-offs between attributes. This study...